SCHEMBL4517291

SCHEMBL4517291

CCOC(=O)CCc1sc2nc(Cc3ccc(Cl)c(Cl)c3)[nH]c(=O)c2c1C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RNASEH1 O60930 1/20 0.46
KDM4E B2RXH2 3/20 0.46
MAPT P10636 2/20 0.46
KMT2A Q03164 7/20 0.45
ALDH1A1 P00352 5/20 0.45
MEN1 O00255 5/20 0.45
PIP4K2A P48426 1/20 0.44
CCNE2 O96020 1/20 0.44
CCNE1 P24864 1/20 0.44
CDK2 P24941 1/20 0.44
LMNA P02545 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
KCNH2 Q12809 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
HPGD P15428 4/20 0.42
L3MBTL1 Q9Y468 3/20 0.41
HTT P42858 1/20 0.41
ATM Q13315 1/20 0.41
TSHR P16473 1/20 0.40
USP2 O75604 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4511602 0.94 HPGD (0.45) RNASEH1KDM4EMAPTKMT2AALDH1A1
SCHEMBL3494138 0.88 RNASEH1 (0.52) RNASEH1KDM4EMAPTKMT2AALDH1A1
SCHEMBL3491779 0.85 RNASEH1 (0.50) RNASEH1KDM4EMAPTKMT2AALDH1A1
SCHEMBL4521433 0.83 ALDH1A1 (0.46) RNASEH1KDM4EMAPTKMT2AALDH1A1
SCHEMBL4514505 0.82 KMT2A (0.65) RNASEH1KDM4EMAPTKMT2AALDH1A1
SCHEMBL3494840 0.82 RNASEH1 (0.54) RNASEH1KDM4EMAPTKMT2AALDH1A1
SCHEMBL16175762 0.78 RNASEH1 (0.54) RNASEH1KDM4EMAPTKMT2AALDH1A1
SCHEMBL3491664 0.78 RNASEH1 (0.58) RNASEH1KDM4EMAPTKMT2AALDH1A1
SCHEMBL21504938 0.77 KMT2A (0.58) RNASEH1KDM4EMAPTKMT2AALDH1A1
SCHEMBL38376 0.77 RNASEH1 (0.52) RNASEH1KDM4EMAPTKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1908765-B1 THIENOPYRIMIDINE DERIVATIVE ASKA PHARM CO LTD (JP) 2014-10-22 EP disclosed
US-8377944-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-02-19 US disclosed
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES GOTANDA KOTARO (JP) 2013-01-24 US disclosed
US-8293754-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-20090203703-A1 Thienopyrimidine Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-08-13 US disclosed
EP-1908765-A1 THIENOPYRIMIDINE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES PDE9A, BPHL, THOP1 RNASEH1 813/4885KDM4E 2859/4885MAPT 1619/4885
US-20090203703-A1 Thienopyrimidine Derivatives PDE9A, BPHL, THOP1 RNASEH1 813/4885KDM4E 2859/4885MAPT 1619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.